Doc code: IDS Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-10)

Approved for use through 07/31/2012. OMB 0651-0031

Mation Disclosure Statement (IDS) Filed

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Application Number		10571311	
	Filing Date		2006-03-09	
	First Named Inventor	WUR	ST	
	Art Unit		1617	
	Examiner Name	SORG	DUSH	
	Attorney Docket Number	er	27234U	

U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	ate	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wisl	h to add	additional U.S. Pater	t citatio	n informa	ation pl	ease click the	Add button.	•	Add	
			U.S.P.	ATENT.	APPLIC	CATION PUBI	LICATIONS		Remove	
Examiner Initial*	Cite N	o Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva	,Columns,Lines wher ant Passages or Rele s Appear	
	1									
If you wisl	h to add	d additional U.S. Publis	shed Ap	plication	citation	n information p	please click the Add	d button	. Add	
				FOREIG	N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*		Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patented Applicant of cited Document	e or  \  I	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	T5
	1									
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials*  Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T5			

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10571311		
Filing Date		2006-03-09		
First Named Inventor	WUR	WURST		
Art Unit		1617		
Examiner Name	SOROUSH			
Attorney Docket Number		27234U		

1	BIBERGER, C., et al., "Efficacy and safety of ciclesonide compared with budesonide in asthma patients: a randomized 12-week study", Presented as a poster at the 99th International Conference of the American Thoracic Society (ATS); May 16-21, 2003; Seattle, Wash., Am J Respir Crit Care Med., 2003; 167: Abstract A1486.	
2	BOULET, L-P., et al., "Ciclesonide is at least as effective as budesonide in the treatment of patients with bronchial asthma", Presented as a poster at the 99th International Conference of the American Thoracic Society (ATS); May 16-21, 2003; Seattle, Wash., Am J Respir Crit Care Med., 2003; 167: Abstract A1508.	
3	BUNDSCHUH, D.S., et al., "[1013] Pre-clinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide", Oral Presentation: New developments in inhaled corticosteroid therapy (2:45 PM - 4:45 PM) Sunday, September 23, 2001, 2:45 PM, Hall 4/5.	
4	DEROM, E., et al., "Efficacy and systemic effects of ciclesonide and fluticasone in asthma patients", Oral presentation at the 11th Annual Congress of the European Respiratory Society (ERS); September 22-26, 2001; Berlin, Germany, Eur Respir J., 2001; 18: Abstract 1015.	
5	ENGELSTÄTTER, R., et al., "Comparative study in asthma patients treated with inhaled ciclesonide (80 μg or 320 μg once daily) or budesonide (200 μg twice daily) for 12 weeks", Presented as a poster at the 99th International Conference of the American Thoracic Society (ATS); May 16-21, 2003; Seattle, Wash., Am J Respir Crit Care Med., 2003; 167: Abstract A1511.	
6	HANSEL, T., et al., "Once daily ciclesonide (80 μg or 320 μg) is equally effective as budesonide 200 μg given twice daily: a 12-week study in asthma patients", Eur Respir J 2003; 22 Suppl 45: 410. Plus poster presented at the 13th Annual Congress of the European Respiratory Society; 2003; September 27-October 1; Vienna; Abstract no. P2639.	
7	KANNIESS, F., et al., "Effect of Inhaled Ciclesonide on Airway Responsiveness to Inhaled AMP, the Composition of Induced Sputum and Exhaled Nitric Oxide in Patients with Mild Asthma", Pulmonary Pharmacology & Therapeutics, (2001), 14, 141-147, © 2001 Academic Press.	
8	SZEFLER, S.J., Deputy Editor, "Early intervention for childhood asthma: Inhaled glucocorticoids as the 'preferred' medication", J Allergy Clin Immunol 1998; 102: 719-721, © 1998 by Mosby, Inc.	
9	UKENA, D., et al., "Ciclesonide significantly improves pulmonary function when compared with budesonide: a randomized 12-week study", Eur Respir J 2003; 22 (Suppl. 45): 411s, Plus poster presented at the 13th Annual Congress of the European Respiratory Society; 2003; September 27-October 1; Vienna; Abstract no. P2640.	
1	WAGENER, J.S., et al., "Inhaled steroids in children: Risks versus rewards", The Journal of Pediatrics, Volume 132, Number 3, Part 1, Pages 381-383, © 1998 by Mosby, Inc.	
If you wish t	o add additional non-patent literature document citation information please click the Add button Add	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10571311		
Filing Date		2006-03-09		
First Named Inventor WURS		ST		
Art Unit		1617		
Examiner Name	SOROUSH			
Attorney Docket Number		27234U		

EXAMINER SIGNATURE					
Examiner Signature		Date Considered			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

----

<sup>&</sup>lt;sup>1</sup> See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.